Functional neutrophils from human ES cells

Slides:

Advertisements

Similar presentations

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Advertisements

Please submit an hSCRO Protocol or modify an existing protocol. (Refer to Provenance policy document, IBC and/or IRB approval may still be required) Do.

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Ann Intern Med. 2011;155(2): doi: / Figure Legend:

Stem Cells & Cancer What? Where? How? Why?.

Pluripotent stem cell based gene therapy for hematological diseases

Gene therapy: efficient targeting of hematopoietic stem cells

Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples by Keiki Kumano, Shunya Arai, Masataka Hosoi, Kazuki.

GVHD-associated immunodeficiency: soil or seed?

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Neoplastic blood cells become pluripotent

Stem cell therapeutic possibilities: future therapeutic options for male-factor and female- factor infertility? Charles A. Easley, Calvin R. Simerly,

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Superior Survival after Autologous vs

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Targeting kinases in CML CLL

Bone morphogenetic protein 4 induces efficient hematopoietic differentiation of rhesus monkey embryonic stem cells in vitro by Fei Li, Shijiang Lu, Loyda.

281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy Molecular Therapy Volume.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Human CD27+IgM+IgD+ B cells: T-cell or TLR-dependent?

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

HU for acute treatment of sickle VOC?

Advances in basic and clinical immunology in 2011

Anergy: the CLL cell limbo

In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation by Carlijn Voermans, Marisha.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Induced pluripotent stem cell technology: A window for studying the pathogenesis of acquired aplastic anemia and possible applications Mahmoud I. Elbadry,

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

Cerebral Organoids in a Dish: Progress and Prospects

Adrian Kee Keong Teo, Amy J. Wagers, Rohit N. Kulkarni Cell Metabolism

Nat. Rev. Nephrol. doi: /nrneph

Pluripotent Stem Cells and Disease Modeling

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Induced pluripotent stem cell modeling of malignant hematopoiesis

Disease modeling of bone marrow failure syndromes using iPSC-derived hematopoietic stem progenitor cells Mahmoud I. Elbadry, J. Luis Espinoza, Shinji.

Induction of Pluripotency: From Mouse to Human

Current Progress in Therapeutic Gene Editing for Monogenic Diseases

S. Tamir Rashid, Graeme J.M. Alexander Journal of Hepatology

Modeling Rett Syndrome with Stem Cells

Moonjung Jung, Cynthia E Dunbar, Thomas Winkler Molecular Therapy

Biology of Blood and Marrow Transplantation

What is quality in a transplant program?

From Skin to Blood: A New Member Joins the iClub

Volume 2(Supplement 1):46-49

Hematopoietic potential of HEP from patient-specific iPSC may be reduced. Hematopoietic potential of HEP from patient-specific iPSC may be reduced. (A)

740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells Molecular Therapy Volume 20, Pages S285-S286.

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation by Richard K. Burt, Ann.

Bridge to transplant following Bv+Bs regimen.

Roberto Ensenat-Waser, Ph. D. , Antonio Pellicer, M. D. , Ph. D

Adult somatic cells to the rescue: nuclear reprogramming and the dispensability of gonadal germ cells Charles A. Easley, Ph.D., David R. Latov, Calvin.

Kazim H Narsinh, Jordan Plews, Joseph C Wu Molecular Therapy

Overview of iPSC applications in biomedical research.

Molecular Obstacles to Clinical Translation of iPSCs

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

INDUCED PLURIPOTENT STEM CELLS (IPSCs)

by Lucy A. Godley, and Akiko Shimamura

by Jan J. Cornelissen, and Didier Blaise

by Lapo Alinari, and Kristie A. Blum

Cellular Alchemy and the Golden Age of Reprogramming

Modeling Brain Disease in a Dish: Really?

Optimizing therapy for nodal marginal zone lymphoma

Presentation transcript:

Functional neutrophils from human ES cells by Colin L. Sweeney, and Harry L. Malech Blood Volume 113(26):6503-6505 June 25, 2009 ©2009 by American Society of Hematology

Treatment of genetic neutrophil disorders using patient-derived induced pluripotent stem cells (iPSCs) capable of producing functional neutrophils. Treatment of genetic neutrophil disorders using patient-derived induced pluripotent stem cells (iPSCs) capable of producing functional neutrophils. Mature cells (fibroblasts or other cell types) could be obtained from the patient and reprogrammed into iPSCs using defined reprogramming factors. Following gene correction or repair, iPSCs could be expanded and differentiated in vitro using the Yokoyama et al or another similar protocol, modified to provide hematopoietic stem cells that are capable of producing functional neutrophils after autologous transplantation. Professional illustration by Marie Dauenheimer. Colin L. Sweeney, and Harry L. Malech Blood 2009;113:6503-6505 ©2009 by American Society of Hematology